| Name | Title | Contact Details |
|---|
To be Hansei is to reflect on the past, learn from mistakes, and commit to doing better in the future. To stop Hansei is to stop learning. Hansei Solutions helps behavioral healthcare facilities nationwide do it better, combining full-service revenue cycle management technology with a personal touch to forge lasting and strategic partnerships. Simply put, Hansei enables providers to collect more, save more, remain compliant, and make more informed decisions impacting their growth and bottom line.
MedAire, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Conifer Health Solutions is a healthcare services company partnering with more than 800 clients to strengthen their financial and clinical performance. Conifer Health helps organizations transition from volume to value-based care, enhance the consumer and patient healthcare experience and improve quality, access to healthcare and control costs. Conifer Health manages more than 24 million unique patient interactions, and $30 billion in net patient revenue and $21.5 billion in medically managed spend. Conifer Health also provides technology and health management services to support care management for 5.7 million lives.
Davids Productions is a Montville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III